Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Statins reduce the risk of atherosclerotic vascular disease in healthy individuals and those with chronic kidney disease (CKD); however, clinical trials have suggested a minimal effect of statins on CKD progression. The PLANET trials compared the renal effects of rosuvastatin and atorvastatin, but the findings leave many questions unanswered.

Original publication

DOI

10.1038/nrneph.2015.36

Type

Journal article

Journal

Nat Rev Nephrol

Publication Date

05/2015

Volume

11

Pages

262 - 263

Keywords

Diabetes Complications, Diabetic Nephropathies, Fluorobenzenes, Heptanoic Acids, Humans, Kidney, Pyrimidines, Pyrroles, Sulfonamides